Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 11/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15263012 | 0.84 | HPGD (0.59) | KDM4EHPGDTSHRALDH1A1GAA | |
| SCHEMBL22138255 | 0.81 | HPGD (0.67) | KDM4EHPGDTSHRALDH1A1KMT2A | |
| SCHEMBL14314758 | 0.80 | HPGD (0.68) | KDM4EHPGDHSD11B1TSHRALDH1A1 | |
| SCHEMBL12569437 | 0.79 | HPGD (0.96) | KDM4EHPGDHSD11B1TSHRALDH1A1 | |
| SCHEMBL2014694 | 0.79 | KDM4E (1.00) | KDM4EHPGDHSD11B1ALDH1A1MAPK1 | |
| SCHEMBL12569383 | 0.78 | HPGD (0.73) | HPGDTSHRALDH1A1KMT2APLA2G7 | |
| SCHEMBL13242359 | 0.78 | HSD11B1 (0.96) | KDM4EHPGDHSD11B1TSHRALDH1A1 | |
| SCHEMBL22840111 | 0.77 | HPGD (0.62) | KDM4EHPGDTSHRALDH1A1MAPK1 | |
| SCHEMBL18354451 | 0.77 | HPGD (1.00) | KDM4EHPGDHSD11B1TSHRALDH1A1 | |
| SCHEMBL11734086 | 0.77 | HPGD (1.00) | KDM4EHPGDHSD11B1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | KDM4E 1495/4885HPGD 2857/4885HSD11B1 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.